Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis

Author:

Abbott MichaelORCID,Ryan Mandy,Hernández Rodolfo,McKenzie Lynda,Heidenreich Sebastian,Hocking Lynne,Clark Caroline,Ansari Morad,Moore David,Lampe Anne,McGowan Ruth,Berg Jonathan,Miedzybrodzka Zosia

Abstract

Abstract Aims This study aims to evaluate the cost effectiveness of genetic and genomic testing strategies for the diagnosis of rare developmental disorders in NHS Scotland. Methods Six genetic and genomic testing strategies were evaluated using a decision tree model. First-line, second-line and last-resort trio genome sequencing (GS), and second-line and last-resort trio exome sequencing (ES) were compared with standard genetic testing. The cost effectiveness of each strategy was expressed in terms of incremental cost per additional diagnosis. The impact of uncertainty on cost-effectiveness results was explored using deterministic and probabilistic sensitivity analysis. Results 2nd-line ES was a cost-saving option, increasing diagnostic yield by 13.9% and decreasing cost by £1027 per trio compared to standard genetic testing. Compared to ES, strategies involving GS increased costs significantly, with only a moderate or zero improvement in diagnostic yield. Sensitivity analysis indicated that significant reductions in cost or improvements in diagnostic yield are required before 1st-line GS becomes cost effective. Conclusion 2nd-line ES (after chromosomal microarray; replacing gene panel testing) for the diagnosis of developmental disorders is a cost-saving option for the Scottish NHS. Ongoing economic evaluation is required to monitor the evolving cost and diagnostic yield of GS and ES over time.

Funder

Chief Scientist Office, Scottish Government Health and Social Care Directorate

Publisher

Springer Science and Business Media LLC

Reference45 articles.

1. The Deciphering Developmental Disorders Study: Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438 (2017). https://doi.org/10.1038/nature21062

2. Scottish Government: rare disease Scotland: Final Progress Report. (2021). Available Online at: https://www.gov.scot/publications/rare-disease-final-progress-report/documents/

3. The Deciphering developmental disorders study: large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223–228 (2014). https://doi.org/10.1038/nature14135

4. De Ligt, J., et al.: Diagnostic exome sequencing in persons with severe exome disability. N. Engl. J. Med. 367, 1921–2929 (2012). https://doi.org/10.1056/NEJMoa1206524

5. Scottish Government: It’s not rare to have a rare disease: The implementation plan for rare diseases in Scotland. (2014). Available Online at: https://www.gov.scot/publications/rare-rare-disease/documents

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3